Guggenheim Cuts Janux Therapeutics (NASDAQ:JANX) Price Target to $58.00

Janux Therapeutics (NASDAQ:JANX) had its price objective dropped by investment analysts at Guggenheim from $68.00 to $58.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 298.60% from the company’s current price.

JANX has been the subject of several other reports. Cantor Fitzgerald decreased their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Piper Sandler decreased their target price on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 16th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. JonesTrading cut their target price on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, April 28th. Finally, Barclays lowered Janux Therapeutics from an “overweight” rating to an “underweight” rating and reduced their target price for the stock from $29.00 to $14.00 in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.92.

Janux Therapeutics Stock Up 0.1%

Janux Therapeutics stock opened at $14.55 on Friday. The firm has a market cap of $887.03 million, a P/E ratio of -7.95 and a beta of 2.58. The business has a fifty day moving average of $14.35 and a two-hundred day moving average of $17.45. Janux Therapeutics has a twelve month low of $12.12 and a twelve month high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. Equities analysts expect that Janux Therapeutics will post -2.34 earnings per share for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently bought and sold shares of the company. BML Capital Management LLC purchased a new stake in Janux Therapeutics during the 1st quarter worth approximately $2,154,000. Allspring Global Investments Holdings LLC purchased a new stake in Janux Therapeutics during the 1st quarter worth approximately $2,452,000. Bleakley Financial Group LLC purchased a new stake in Janux Therapeutics during the 1st quarter worth approximately $265,000. Hsbc Holdings PLC purchased a new stake in Janux Therapeutics during the 1st quarter worth approximately $711,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Janux Therapeutics during the 1st quarter worth approximately $1,946,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.